Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...

Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...

The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...

Divi’s Laboratories Ltd reported 40.84% increase in revenues yoy for the Q4FY22 quarter on consolidated basis at Rs2,518.44 crore. On a sequential basis, revenues were up for the quarter by 1.01%.

Dr Murali Krishna Prasad Divi's resilience and strategic decisions have propelled Divi’s Labs to global success as a top API manufacturer. The company's commitment to chemistry and customer ...

The FDA, which last month banned APIs coming from a Divi’s Laboratories plant in India, has followed that up with a warning letter that savages the facility for refusing to give inspectors records ...

Divi’s Laboratories reported 46.54% yoy rise in total sales revenues for the Dec-21 quarter on consolidated basis at Rs2,493cr. On a sequential basis, the revenues were up by 25.45%. During the ...

Hyderabad-based pharmaceutical company, Divi’s Laboratories came to the limelight during the Covid-19 pandemic when the demand for Molnupiravir, an anti-viral drug, peaked during the period, with the ...